Palvella Therapeutics reports FY2024 net loss $17.4M, cash $83.6M; SELVA top-line Q1 2026 on track

PALVELLA THERAPEUTICS, INC.

2025-Q1 EPS reported -$0.74

Net loss $17.4M ($7.83/share) vs net income $17.9M in FY2023; R&D expense $8.2M, G&A $5.9M.
Cash and equivalents $83.6M, expected to fund operations into H2 2027.
Completed merger and $78.9M private placement in Dec 2024 with BVF, Frazier Life Sciences.
Phase 3 SELVA top-line Q1 2026; Phase 2 TOIVA top-line Q4 2025; both for QTORIN rapamycin.
Plans to expand QTORIN pipeline with new indication and product candidate in H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.